{"entity":{"id":"nct04539496","kind":"trial","name":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of XZP-3287 and Fulvestrant in advanced solid tumours, run by Sihuan Pharmaceutical Holdings Group Ltd., active and no longer recruiting.","summary":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors is a phase 1/2 interventional study registered as NCT04539496 by Sihuan Pharmaceutical Holdings Group Ltd., with 402 participants enrolled, started 2018-05-22 and due to reach its primary completion in 2023-07-31. Interventions recorded: XZP-3287 and XZP-3287;Letrozole;Anastrozole;Fulvestrant.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04539496","url":"https://clinicaltrials.gov/study/NCT04539496"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["xzp-3287","fulvestrant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04539496","phase":"1/2","setting":"A Multicenter, Open-label Phase I/II Study of XZP-3287 in Metastasis Solid Tumors in China","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","enrolled":402,"outcomes":[]},"route":"/trials/nct04539496/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"xzp-3287","kind":"drug","name":"XZP-3287","route":"/drugs/xzp-3287/"}]}}